Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 26;85(5):704–714. doi: 10.1002/ana.25450

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Time‐action curve for UPDRS‐III for threshold and suprathreshold infusions of intravenous levodopa at baseline and approximately 6 months after administration of VY‐AADC01. The figure shows the UPDRS‐III time‐action curves following a threshold (0.6 mg/kg/h; left side) and suprathreshold (1.2 mg/kg/h; right side) intravenous dose of levodopa by cohort (A,B: cohort 1; C,D: cohort 2; E,F: cohort 3). Lower scores indicate improvement. Dashed lines in each figure show data before VY‐AADC01 administration and solid lines postadministration. The gray box shows the actual infusion time. Note in cohort 2 the time‐action curve for threshold (low‐dose) intravenous levodopa post‐VY‐AADC01 administration (C) appears similar to the suprathreshold (high‐dose) intravenous levodopa pre‐VY‐AADC01 administration (D). AUC = area under the curve; UPDRS = Unified Parkinson's Disease Rating Scale.